MyCoPlan-The New Web Based Networking Portal for Investors and Entrepreneurs

VEYTAUX, SWITZERLAND, Jun 01 (MARKET WIRE) —
MyCoPlan –

www.mycoplan.com is the new website for entrepreneurs seeking funds in
order to implement their commercial project as well as for investors
looking to invest in the creation of new companies.

By connecting entrepreneurs and investors, we fulfill our mission which
consists in facilitating the first step to create a company: raise funds.

How does it work? By using our user-friendly online forms, the
entrepreneur shares with us the executive summary of his business plan.

Once approved by our team, his executive summary is posted on our website
for 1 year and dispatched by email to our investors’ network.

In terms of costs, this to encourage the creation of new businesses, our
pricing policy is set to be clear and highly competitive. One single fee:
publishing a project on www.mycoplan.com costs only (GBP 45.- / US$80.- /
CAN$80.-) per year. This fee includes all of our services: pre read of
the project, validation, publication on our website as well as sharing
the projects with our investors’ network.

The “ProjectPool”:

Furthermore, bearing in mind that our goal is to promote the creation of
new companies, www.mycoplan.com sponsors once a year the launch of the
most creative idea.

For each executive summary published on our website, an amount of (UK:
GBP 9.- / US$ 15.- / CAN$15.-) is collected at our expense in our
“Project Pool”. Once a year, and during 1 month, our website
visitors are invited to vote for the most creative, deserving and
original project (and realistic of course!). At the end of the vote, the
entrepreneur who has garnered the most votes and has not yet found an
investor will win the entire “Project Pool”!

www.mycoplan.com is active since the 1st of June 2010 and is available in
8 countries: UK, USA, Canada, Switzerland, Germany, France, Belgium and
Austria.

Possibility to exchange links on our website for all companies
(investors, media, etc) willing to include their logo&link on
www.mycoplan.com.

Contacts:
MyCoPlan
Florian Vernier
0041 (0) 79 262 22 59
info@mycoplan.com
www.mycoplan.com

Copyright 2010, Market Wire, All rights reserved.

Parliament passes bill for better care of ancient monuments

New Delhi, March 16 (IANS) Parliament Tuesday passed a bill amending and making more stringent the law for protection of ancient sites and monuments and constituting an expert committee to look after their conservation.

The bill, which was passed by the Lok Sabha Monday, was approved by the Rajya Sabha Tuesday.

The bill, which seeks to replace an ordinance by President Pratibha Patil, aims to strengthen the Ancient Monuments and Archaeological Sites and Remains Act, 1958, and imposes stringent punishment on the violators of the act’s provisions.

The Ancient Monuments and Archaeological Sites and Remains (Amendment and Validation) Bill, 2010, piloted by Law and Justice Minister Veerappa Moily, stipulates that a minimum area of 100 metres in all directions of the protected monuments and sites shall be declared prohibited for purposes of construction and no private or public construction in the prohibited area will be allowed except those undertaken by the Archaeological Survey of India (ASI).

The ASI will be responsible for the upkeep, maintenance and management of the protected monuments and sites.

The bill says in addition to the 100 metres of prohibited area around the site, a minimum area of 200 metres in all directions of the protected site will be regulated.

No construction will also be allowed on these areas, ‘except in accordance and permitted by extent of the heritage bylaws’ which will have to be approved by the central government which might extend it more than 200 metres.

The bill recommends the constitution of National Monument Authority, an expert committee which will look after conservation of heritage.

Rajya Sabha adjourned till April 12

New Delhi, March 16 (IANS) The Rajya Sabha was adjourned Tuesday for the inter-session recess and will meet again April 12 for the remaining part of the budget session.

Deputy Chairman K. Rahman Khan adjourned the house after it passed the Ancient Monuments and Archaeological Sites and Remains (Amendment and Validation) Bill, 2010.

The House earlier in the day passed the Appropriation (Vote on Account) Bill, 2010, and the Appropriation Bill, 2010, and returned these to the Lok Sabha.

The budget session of parliament began Feb 22 and is slated to conclude May 7.

Meditation a good way to ease pain

Washington, Mar 16 (ANI): Meditation can help enhance the ability to moderate reactions to pain, according to new study.

In the study, published in The Journal of Pain, boffins from the University of North Carolina measured pain ratings in students interested in learning meditation who recruited for the study. Subjects were trained in meditation for three consecutive days and were given experimental pain stimuli.

Results of the trial showed that relaxed states promoted by the brief mindfulness meditation sessions reduced the reported pain ratings. Participants had less pain to both low and high pain intensities and showed significant reductions in anxiety after each meditation stimulation. The authors concluded that decreases in anxiety and increases in the ability to sustain personal focus can attenuate the feeling of pain.

In assessing their findings, the authors noted that the analgesic effects of meditation can be realized even after a short period of time learning the technique. Also, the results provide additional validation of the benefits of cognitive techniques for controlling pain. (ANI)

Cabinet approves recognition of ancient Sowa-Rigpa medical system

New Delhi, Sep 10 (ANI): The Union Cabinet today approved the Indian Medicine Central Council (Amendment) Bill, 2009 for amending the Indian Medicine Central Council Act, 1970.

“Sowa-Rigpa” commonly known as ‘Amchi’ is one of the oldest surviving system of medicine in the world, popular in the Himalayan region of India. In India this system is practiced in Sikkim, Arunachal Pradesh, Darjeeling (West Bengal), Lahoul and Spiti (Himachal Pradesh) and Ladakh region of Jammu and Kashmir.

The theory and practices of “Sowa-Rigpa” are similar to Ayurveda, and also include few principles of Traditional Chinese Medicine. The fundamental text book rgyud-bzi of “Sowa-Rigpa” is believed to have been taught by Buddha himself and is closely linked with Buddhist philosophy. he Government of India has received representations from various quarters to grant recognition to the System of “Sowa-Rigpa” to enable it get a legal status.

To confer legal status to “Sowa-Rigpa” amendments to section 2,3,8,9 and 17 of the Indian Medicine Central Council Act 1970, need to be carried out.

The proposed amendments shall give effect to the inclusion of “Sowa-Rigpa” under sections 2,3,8,9 and 17 of the Indian Medicine Central Council Act, 1970 thereby recognizing this system legally.

It is expected that the legal recognition of “Sowa-Rigpa” will lead to the protection and preservation of this ancient system of medicine and will help in its propagation and development. This will also open new vistas leading to collaborative research and scientific validation of the “Sowa-Rigpa” system, besides conservation and protection of the medicinal plants/minerals used in the system.

The recognition of “Sowa-Rigpa” will also lead to the setting up of a mechanism to regulate the education and practice of “Sowa-Rigpa”. (ANI)

National Literacy Mission to substantially focus on women: Sibal

New Delhi, Aug 21(ANI): The Government on Friday said that the National Literacy Mission is being recast, so that, 80 per cent coverage of the mission is of women, whose literacy rate at present is at an unacceptable level of 54 per cent.

Union Minister for Human Resource Development Kapil Sibal said this while chairing the 11th Meeting of the National Literacy Mission Authority (NLMA) here on Friday.

Sibal informed NLMA members that while the total budgetary support during the last three plans for the programme was Rs. 2862.95 crore, the outlay for the 11th plan was at a much higher level of Rs.6000 crore.

Sibal said that the Mission would be run in active participation with the State Governments unlike in the past when the mission was run directly from the centre through the different implementation agencies at the district level.

He also said that Adult Education Centres would be set up at the Gram Panchayat, which will be the unit for implementation of the programme.

He also informed that the Panchayat would work in tandem with the community to implement the programme.

Sibal further highlighted that a Curriculum Framework for Adult Literacy will be developed with adequate reflection of locally relevant issues and aspects.

He pointed out that unlike in the past, each learner will be tagged and tracked for the learning achievement. Besides an efficient MIS system, concurrent monitoring systems will be put in place for field validation.

Thirty two of the forty four members of the NLMA participated in the meeting, which passed the agenda put before it.

Union Minister for Rural Development C.P. Joshi, Minister of State for Human Resource Development D. Purandeswari, Secretary for Department of School Education and Literacy Anshu Vaish, were among those present in the meeting. (ANI)

Donate your computer’s idle time to find cure for HIV, Parkinson’s, breast cancer

Washington, June 21 (ANI): Your computer can be put to good use even when its not in use, for now it’s possible to donate the idle time to cutting-edge biomedical research aimed at finding a cure for HIV, Parkinson’s, arthritis, and breast cancer.

University of Delaware’s “Docking@Home” project, led by Michela Taufer, assistant professor of computer and information sciences, allows people to donate their computer’s idle time to perform scientific calculations that will aid in creating new and improved medicines to thwart these major diseases.

Taufer explained that researchers should create molecular models and simulate their interactions to reveal possible candidates for effective drugs, which could then be put under laboratory testing. And such a simulation is called “docking”.

As there are infinite combinations of molecules and their binding orientations, simulating them requires tremendous computing power.

Supercomputers often have a long waiting line or are too expensive to use for extended periods, said Taufer.

Thus, researchers have turned to citizen volunteers for help, which enables them to distribute the hundreds of thousands of computing tasks across a large number of computers.

Although the research is still in the validation stage, the process is aimed at studying new drugs.

“We are transforming a process in nature into computer steps-an algorithm,” explained Taufer.

To volunteer your computer’s idle time to do scientific calculations, it takes only a few simple steps highlighted on the project Web page (http://docking.cis.udel.edu/).

One can install a free, open-source software program called BOINC (Berkeley Open Infrastructure for Network Computing), developed at the University of California, and link up to the Docking Server at the University of Delaware to become part of the network.

The computer’s idle cycles are accessed automatically when it is not in use.

Currently, the 6,000 volunteers worldwide who currently are involved in UD’s Docking@Home project are contributing to the completion of some 30,000 docking tasks per day, said Taufer. (ANI)

Newly found genes linked with menopause could prevent cancer, heart disease

London, May 18 (ANI): Scientists have found new gene variants linked with the age at which females experience their first menstrual period and the onset of menopause, which can even help in preventing breast and endometrial cancer and osteoporosis, and cardiovascular disease.

In the collaborative study led by Harvard School of Public Health (HSPH), the researchers have identified 10 genetic variants in two chromosomal regions associated with age at menarche (the first menstrual period), and 13 genetic variants in four chromosomal regions associated with age at natural menopause.

Menarche and natural menopause are two important physiological events in a woman’s life.

The researchers explained that an early onset of menarche and later menopause are well-established risk factors for the development of breast cancer and endometrial cancer.

On the other hand, early menopause increases risk of osteoporosis and cardiovascular disease.

Previous studies have suggested both menarche and menopause may be partially under genetic control.

And thus, to identify common genetic variants influencing these states, the researchers analysed more than 317,000 gene variants in a total of 17,438 women from the Nurses’ Health Study (NHS) and the Women’s Genome Health Study (WGHS) based at BWH.

“At these newly identified loci, fine mapping or sequencing might lead to identification of the causal variants, and thus expand our knowledge of the underlying physiology and biological regulation of these traits. Insights into the genetic factors influencing the timing of menarche and natural menopause might shed light on normal reproductive function and the prevention of the diseases associated with these two traits,” Nature magazine quoted lead author Chunyan He, a doctoral student at HSPH, as saying.

Daniel Chasman, Director of Computational Biology in the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, said:

“The collaboration of the WGHS and the NHS represents a great example of how large cohorts with genome-wide data can complement each other. While only one locus reached near genome-wide significance in the NHS alone, the meta-analysis of combined data had much more statistical power and revealed a total of two loci for timing of menarche and four for timing of menopause.”

Chasman, also an assistant professor at Harvard Medical School, added: “Of the loci for timing of menopause, three were already strong but not proven candidates in the NHS; these loci reached genome-wide significance in the WGHS alone, supplementing the meta-analysis by a second mode of validation through replication. The remaining locus, for timing of menopause, would not have been identified, even as a candidate, without the joint power of these two cohorts working together.

“Future collaborations will hopefully continue to leverage the combined power of the two cohorts for association studies directed at other clinical characteristics.”

Titled ‘Genome-wide association studies identify loci associated with age at menarche and at natural menopause’, the study has been published online in Nature Genetics. (ANI)

Ocimum Biosolutions to introduce new test for H1N1 flu

Hyderabad, May 4 (ANI/Business Wire India): Ocimum Biosolutions announced the launch of a microarray-based test (research use only) for the latest version of the H1N1 flu.

The company reported that it updated its custom chip probes using sequence information from the latest strain of the swine flu from the NCBI site.

Most of these sequences have been submitted worldwide in the past 96 hours.

The CDC and US Food and Drug Administration have authorized the emergency use of an RT-PCR based molecular diagnostic assay to identify cases of swine flu in the current outbreak in the US.

The microarray (research use only) was developed on Ocimum’s custom OciChipT array platform three years ago when the first cases of the avian flu outbreak occurred.

This has been updated with the latest sequence information posted last week and the probes have been redesigned.

This test will be available for use after the validation is completed. Ocimum said that it can also provide an RT-PCR based molecular diagnostic assay for use in India and Asia.

Anu Acharya, CEO, Ocimum Biosolutions said, “Our Bioinformatics team in India has redesigned the OciChipT array probes to match the latest sequence information available. The RT-PCR assay and the microarray will quickly identify the H1N1 virus in patients diagnosed with Influenza A as some older tests may not pick up this new strain.”

“In a public health emergency like this, we want to make sure that we identify the right strain which is not picked up by current tests. We are ready to work with various public health labs in the India and the region that need help in setting up these assays, or running the samples in our labs. Pandemics of this sort need to be rapidly identified at the source so that public health officials can implement various measures to control the disease. Both these assays can be conducted in a few hours and avoids the risk of patients with suspected cases infecting others when the wait is longer,” added Acharya. (ANI)

Piramal Healthcare to shut down one UK unit

Piramal Healthcare Ltd plans to shut one of its drug units in the UK to help control costs, booking a one-time hit of 710 million rupees in the quarter ended March, company officials said on Wednesday.

“We realised that within our system we could shift whatever … we are manufacturing at Huddersfield to other locations and thereby save a considerable amount of cost,” Chairman Ajay Piramal said on an investors call.

The unit in Huddersfield had revenue of 19 million pounds in the fiscal FY09, R. Ananthanarayanan, director, pharma solutions, said on the call.

Production will be shifted to other Piramal units in UK and India, Ananthanarayanan added. Piramal will have to run validation processes in these before the products can be manufactured there, delaying the revenue flow, he added.

This, coupled with high inventory build-up at several of Piramal’s clients, will see FY10 revenue from pharma solutions coming in 5 percent lower from a year earlier, he added.

Operating margins, however, is expected to improve by 6-8 percent due to a combination of the shutdown and a focus on high margin businesses including clinical packaging, and early phase manufacturing, he added.

With more business being moved to its Indian units, he sees revenue from the India-based custom manufacturing business growing 15 percent.

Piramal will continue to operate its two other drug-making units in the UK, including the one acquired from Pfizer in 2006. At the time of purchase, Piramal also secured contracts to make various products for Pfizer.

The U.S. drug giant has renewed about 25 percent of these contracts, with the rest under finalisation, he said.

Novel stem cell therapy may treat deafness

Washington, Mar 29 (ANI): In a breakthrough study, researchers have developed a new stem cell therapy that may help in treating hearing impairment.

Deafness typically involves the loss of sensory receptors, called hair cells, for their “tufts” of hair-like protrusions, and their associated neurons.

Led by Dr. Marcelo N. Rivolta of the University of Sheffield, researchers have has successfully isolated human auditory stem cells from foetal cochleae (the auditory portion of the inner ear) and found that they could be differentiated into sensory hair cells and neurons.

The researchers carefully dissected and cultured cochlear cells from 9-11 week-old human fetuses.

They then expanded the cells and maintained in vitro for up to one year, with continued division for the first 7 to 8 months and up to 30 population doublings, which is similar to other non-embryonic stem cell populations, such as bone marrow.

Gene expression analysis showed that all cell lines expressed otic markers that lead to the development of the inner ear as well as markers expressed by pluripotent embryonic stem cells, from which all tissues and organs develop.

The researchers could formulate conditions that allowed for the progressive differentiation into neurons and hair cells with the same functional electrophysiological characteristics as cells seen in vivo.

“The results are the first in vitro renewable stem cell system derived from the human auditory organ and have the potential for a variety of applications, such as studying the development of human cochlear neurons and hair cells, as models for drug screening and helping to develop cell-based therapies for deafness,” said the authors.

Although the hair cell-like cells did not show the typical formation of a hair bundle, the authors suggest that future studies will aim to improve the differentiation system.

Now, the researchers are working on using the knowledge from this study to optimise the differentiation of human embryonic stem cells into ear cell types.

“Although considerable information has been obtained about the embryology of the ear using animal models, the lack of a human system has impaired the validation of such information,” noted the authors.

Dr Ralph Holme, director of biomedical research for Royal National Institute for Deaf and Hard of Hearing People, said: “There are currently no treatments to restore permanent hearing loss so this has the potential to make a difference to millions of deaf people.”

The study is published in the April issue of Stem Cells. (ANI)

Now, biomarker test to diagnose or rule out Alzheimer’s disease

Washington, Mar 17 (ANI): In a breakthrough study, researchers at the University of Pennsylvania School of Medicine have pioneered a biomarker test that can confirm or rule out Alzheimer’s disease.

The test measures cerebrospinal fluid (CSF) concentrations of two of the disease’s biochemical hallmarks – amyloid beta42 peptide and tau protein.

With this information in hand, the scientists also predict whether a person’s mild cognitive impairment would convert to Alzheimer’s disease over time.

The research team, led by Dr. Leslie M. Shaw, Co-Director of the Penn Alzheimer’s Disease Neuroimaging Initiative (ADNI) Biomarker Core, could detect this devastating disease at the earliest stages, before dementia symptoms appeared and widespread irreversible damage occurred.

By improving upon a previously suggested pathological CSF biomarker signature, the researchers found evidence of neuron degeneration – marked by an increase in CSF concentration of tau proteins – and plaque deposition, indicated by a decrease in amyloid beta42 concentration.

Also, people with two copies of the genetic risk factor for Alzheimer’s disease, APOE e4 , had the lowest concentrations of amyloid beta42, compared to those with one or no copies.

“With this test, we can reliably detect and track the progression of Alzheimer’s disease,” said Shaw.

He added: “Validated biomarker tests will improve the focus of Alzheimer’s clinical trials, enrolling patients at earlier stages of the disease to find treatments that can at least delay -and perhaps stop- neurodegeneration. In addition, prevention trials can test methods to delay or block mild cognitive impairment from converting to full-blown Alzheimer’s.”

Currently, researchers are conducting further validation studies of the research test system.

Additional work is needed to develop additional biomarkers, as well as identify more genetic risk factors that will help distinguish Alzheimer’s from other neurodegenerative diseases characterized by cognitive impairments.

The study appears in the online edition of the Annals of Neurology. (ANI)